Shanghai Henlius Biotech, Inc. Class HShanghai Henlius Biotech, Inc. Class HShanghai Henlius Biotech, Inc. Class H

Shanghai Henlius Biotech, Inc. Class H

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪43.48 B‬HKD
1.65HKD
‪889.57 M‬HKD
‪6.21 B‬HKD
‪47.18 M‬
Beta (1Y)
0.32
Employees (FY)
‪3.52 K‬
Change (1Y)
−122 −3.35%
Revenue / Employee (1Y)
‪1.77 M‬HKD
Net income / Employee (1Y)
‪253.08 K‬HKD

About Shanghai Henlius Biotech, Inc. Class H


CEO
Jun Zhu
Headquarters
Shanghai
Founded
2010
ISIN
CNE100003N76
FIGI
BBG00Q3NTQ54
Shanghai Henlius Biotech, Inc. engages in the production and sale of monoclonal antibody (mAb) drugs and the provision of related consultation and technical services, and the transfer of its own technology. It operates through the Mainland China and Overseas geographical segments. The company was founded by Wei Dong Jiang and Shi Gao Liu in 2010 and is headquartered in Shanghai, China.

Check out other big names from the same industry as 2696.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 2696 is 79.05 HKD — it has decreased by −3.75% in the past 24 hours. Watch Shanghai Henlius Biotech, Inc. Class H stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange Shanghai Henlius Biotech, Inc. Class H stocks are traded under the ticker 2696.
2696 stock has fallen by −3.69% compared to the previous week, the month change is a 10.00% rise, over the last year Shanghai Henlius Biotech, Inc. Class H has showed a 242.95% increase.
We've gathered analysts' opinions on Shanghai Henlius Biotech, Inc. Class H future price: according to them, 2696 price has a max estimate of 130.05 HKD and a min estimate of 70.63 HKD. Watch 2696 chart and read a more detailed Shanghai Henlius Biotech, Inc. Class H stock forecast: see what analysts think of Shanghai Henlius Biotech, Inc. Class H and suggest that you do with its stocks.
2696 reached its all-time high on Aug 26, 2025 with the price of 85.95 HKD, and its all-time low was 9.60 HKD and was reached on Oct 6, 2023. View more price dynamics on 2696 chart.
See other stocks reaching their highest and lowest prices.
2696 stock is 5.13% volatile and has beta coefficient of 0.32. Track Shanghai Henlius Biotech, Inc. Class H stock price on the chart and check out the list of the most volatile stocks — is Shanghai Henlius Biotech, Inc. Class H there?
Today Shanghai Henlius Biotech, Inc. Class H has the market capitalization of ‪42.34 B‬, it has decreased by −2.69% over the last week.
Yes, you can track Shanghai Henlius Biotech, Inc. Class H financials in yearly and quarterly reports right on TradingView.
Shanghai Henlius Biotech, Inc. Class H is going to release the next earnings report on Mar 24, 2026. Keep track of upcoming events with our Earnings Calendar.
2696 net income for the last half-year is ‪419.06 M‬ HKD, while the previous report showed ‪470.99 M‬ HKD of net income which accounts for −11.03% change. Track more Shanghai Henlius Biotech, Inc. Class H financial stats to get the full picture.
No, 2696 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 3, 2025, the company has ‪3.52 K‬ employees. See our rating of the largest employees — is Shanghai Henlius Biotech, Inc. Class H on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Shanghai Henlius Biotech, Inc. Class H EBITDA is ‪1.38 B‬ HKD, and current EBITDA margin is 21.68%. See more stats in Shanghai Henlius Biotech, Inc. Class H financial statements.
Like other stocks, 2696 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Shanghai Henlius Biotech, Inc. Class H stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Shanghai Henlius Biotech, Inc. Class H technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Shanghai Henlius Biotech, Inc. Class H stock shows the buy signal. See more of Shanghai Henlius Biotech, Inc. Class H technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.